ZURICH (Reuters) - A surge in demand for Roche’s COVID-19 tests, as some governments even sent military jets to pick up supplies, failed to offset the hit to other parts of the healthcare company’s business from the COVID-19 pandemic, it said on Thursday.
Shares in the Swiss group slipped 1.5% in early trading after it reported a 10% drop in second-quarter revenue to 14.1 billion Swiss francs ($15.2 billion). Factoring out the strong Swiss franc, revenue fell 4%.
Roche joined Swiss rival Novartis in reporting patients skipped hospital or doctor visits, instead hunkering down at home amid COVID-29 lockdowns.
Roche’s multiple sclerosis drug Ocrevus, haemophilia treatment Hemlibra, eye drug Lucentis and blood cancer treatment Rituxan all took a beating, as the pandemic “continues to pose an enormous challenge worldwide,” CEO Severin Schwan said.
COVID-19 diagnostics demand skyrocketed, with Roche testing head Thomas Schinecker saying orders for equipment soared to record levels.
“The orders we’ve gotten are as high as what we would normally sell in four to five years,” he said. “We even had governments that flew in with military planes to pick up instruments.”
Roche said several countries offered to send planes, but didn’t name them.
First-half net income fell 5% year on year to 8.5 billion francs, while sales slipped 4% to 29.3 billion francs.
The Basel-based company stuck to its 2020 outlook, saying an uptick in revenue that started in June bolstered confidence that full-year sales would grow in the low- to mid-single-digit percentage range at constant exchange rates, with core earnings per share growth roughly matching that.
Roche still expects to be able to hike its dividend.
“Even though treatments were delayed, as of June, we’ve seen a strong recovery,” Schwan said. “It’s really based on this recovery that we feel confident to also confirm the initial outlook.”
($1 = 0.9278 Swiss francs)
Reporting by John Miller; Editing by Lincoln Feast and Mark Potter
Our Standards: The Thomson Reuters Trust Principles.